{
  "symbol": "GILD",
  "name": "Gilead Sciences",
  "sector": "Health Care",
  "industry": "Biotechnology",
  "date_added": "2004-07-01",
  "headquarters": "Foster City, California",
  "founded": "1987",
  "market_cap": 140029.198336,
  "pe_ratio": 23.649158,
  "forward_pe": 15.150741,
  "eps": 4.76,
  "revenue": 28735.000576,
  "profit_margin": 0.20759001,
  "debt_to_equity": 130.789,
  "return_on_equity": 0.32654998,
  "dividend_yield": 2.85,
  "current_price": 112.59500122070312,
  "year_high": 118.28405949217839,
  "year_low": 64.26731191999214,
  "price_change_1d": 1.382139110258424,
  "price_change_1w": 0.7741858388800025,
  "price_change_1m": 2.6565970160549397,
  "description": "Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive f",
  "website": "https://www.gilead.com",
  "employees": 17600,
  "exchange": "NMS",
  "currency": "USD",
  "analyst_target_price": 116.76846,
  "recommendation": 1.86207,
  "number_of_analysts": 26,
  "earnings_history": [],
  "analyst_data": {
    "target_high": 140.0,
    "target_low": 93.0,
    "target_mean": 116.76846,
    "target_median": 118.5
  },
  "last_updated": "2025-07-09T11:22:36.771312",
  "data_quality": {
    "has_financial_data": true,
    "has_earnings_data": false,
    "has_analyst_data": true,
    "completeness_score": 0.6666666666666666
  }
}